Biocytogen is dedicated to the discovery and development of novel antibody-based drugs to meet unmet medical needs, with a particular focus on oncology, autoimmune, inflammatory, metabolic, and other diseases. The company’s current assets include monoclonal antibodies, bispecific antibodies, bispecific ADCs, etc. By advancing its R&D capabilities and establishing key partnerships for licensing and co-development opportunities, Biocytogen aims to deliver transformative therapies to patients in need.
To learn more about our assets, or to explore licensing/co-development opportunities. please contact [email protected].
Therapeutic Area |
Product |
Target(s) |
Partner |
Molecular Format |
Indication(s) |
Status |
Oncology |
YH003 |
CD40 |
mAb | Solid tumors | Phase 2 | |
| YH001 |
CTLA-4 |
TRACON | mAb | Solid tumors | Phase 1->Phase 2 | |
| YH002 |
OX40 |
mAb | Solid tumors | Phase 1 | ||
| YH004 |
4-1BB |
mAb | Solid tumor | Phase 1 | ||
| YH008 |
PD-1 x CD40
|
Chipscreen NewWay | BsAb | Solid tumors | Phase 1 | |
| YH012 | HER2 x TROP2 | BsADC | Solid tumors | Pre-clinical | ||
| YH013 | EGFR x MET | BsADC | Solid tumors | Pre-clinical | ||
| YH016 |
Undisclosed
|
Oncology | Discovery | |||
| TNFR2 | Dragonboatbio | mAb | Solid tumors | IND | ||
| BCG008 | SIGLEC15 | Undisclosed | mAb | Solid tumors | Pre-clinical | |
| BCG011 | TROP2 x EGFR | Doma | BsADC | Oncology | Pre-clinical | |
| BCG012 | HER3 x MUC1 | Doma | BsADC | Oncology | Pre-clinical | |
| B7-H3 | Mabworks | mAb | Solid tumors | Discovery | ||
| BCG005 |
CCR8
|
LiberoThera | mAb | Solid tumors | Discovery | |
| AMHR2 | Undisclosed | mAb | Solid tumors | Discovery | ||
| BCG006 | WT1 | Undisclosed | TCRm | Oncology | Discovery | |
| BCG010 |
NKG2A
|
Undisclosed | mAb | Oncology | Discovery | |
| BCG013 | 5T4 x MET | Doma | BsADC | Oncology | Discovery | |
| Inflammation and Autoimmunity |
CD40 inhibitor | mAb | Autoimmunity | Pre-clinical | ||
|
YH017
|
Undisclosed | Autoimmunity | Discovery | |||
| Infectious Diseases |
BCG004
|
Rabies virus | Undisclosed | mAb | Infectious Diseases | Discovery |
| Rare Diseases |
BCG009
|
Undisclosed | Undisclosed | mAb | Rare Diseases | Discovery |
Learn more about our antibody hits library here.
